Monitor the prospectus supplement for the actual offering size and pricing. The use of proceeds to repay debt suggests financial strain; watch for any subsequent filings indicating the company's cash runway.
CTSO drugs
CTSO drug pipeline →Price Chart
How similar events traded
Executive Summary
CytoSorbents entered into two securities purchase agreements to raise an undisclosed amount through a registered direct offering of common stock and pre-funded warrants, with H.C. Wainwright and WBB Securities as placement agents. Net proceeds will be used to repay up to $3 million of debt under the Avenue Capital Group loan and for general corporate purposes. The offering is highly dilutive given the company's $14 million market cap.
Key Facts
- Company entered into two securities purchase agreements for a registered direct offering of common stock and pre-funded warrants.
- Aggregate offering size is undisclosed (placeholder amounts in documents).
- Placement agents are H.C. Wainwright & Co. (first agreement) and WBB Securities (second agreement).
- Net proceeds to be used for repayment of up to $3 million of debt under the Avenue Capital Group loan and general corporate purposes.
- Pre-funded warrants have an exercise price of $0.001 per share.
- Company market cap is $14 million, making any offering size material.
- The offering is registered under an existing S-3 shelf (File No. 333-281062).
Financial Impact
Undisclosed amount; given $14M market cap, even a modest raise represents significant dilution.
Risk Factors
- Highly dilutive equity offering at a micro-cap company with a $14M market cap.
- Undisclosed offering size creates uncertainty about the magnitude of dilution.
- Debt repayment use of proceeds signals potential liquidity constraints.
- Pre-funded warrants at $0.001 exercise price will likely be exercised immediately, adding to dilution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-130442 |
| Document: tm2630144d1_ex10-2.htm | 0001104659-26-130442 |
| Document: tm2630144d1_ex4-2.htm | 0001104659-26-130442 |
Track record
12 reports on CTSO
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +36.94% at T+60 after the Aug 6, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 20, 20261d ago 424B5 Bearish 6/10 Entry $5.39 Now $4.16 +22.82% settles Feb 19
- Nov 20, 20261d ago 8-K Bearish 6/10 Viewing Entry $5.39 Now $4.16 +22.82% settles Feb 19
- Nov 19, 20263d ago 8-K/A Neutral 4/10 Entry $5.13 Now $4.16 −18.91% settles Feb 18
- Nov 17, 20265d ago NT 10-Q Neutral 4/10 Entry $4.52 Now $4.16 −7.96% settles Feb 16
- Nov 12, 20269d ago Press Release Neutral 4/10 Entry $4.87 Now $4.16 −14.58% settles Feb 11
- Nov 12, 20269d ago 8-K Neutral 5/10 No price data
- Sep 23, 20268w ago 8-K Mixed 5/10 Entry $4.91 Now $4.16 −15.27% settles Dec 17
- Aug 6, 202615w ago Press Release Bearish 6/10 Entry $0.3600 to $0.2270 Now $4.16 −1055.56% ▲ +36.94% +34.68% vs SPY
- Jun 25, 202621w ago DEFA14A Neutral 3/10 Entry $0.3620 to $0.2660 Now $4.16 +1049.17% ▼ −26.52% −32.61% vs SPY
- Jun 16, 202622w ago Insider Cluster Bullish 6/10 Entry $0.5189 to $0.3205 Now $4.16 +701.70% ▼ −38.23% −40.10% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers